Factors Affecting Relapse and Remission in Behçet's Uveitis Treated with Interferon Alpha2a

Area of Science:

• Ophthalmology
• Immunology
• Rheumatology

Background:

• Behçet uveitis (BU) is a chronic inflammatory condition affecting the eyes.
• Managing relapses and achieving sustained remission in BU is clinically challenging.
• Interferon alpha2a (IFNα2a) therapy is used for severe cases of BU.

Purpose of the Study:

• To identify factors influencing relapse and remission in Behçet uveitis patients treated with interferon alpha2a (IFNα2a).
• To evaluate the efficacy of IFNα2a in reducing the frequency of uveitis attacks.

Main Methods:

• Retrospective review of clinical records for 32 patients (54 eyes) with severe BU treated with IFNα2a.
• Analysis of factors including age, gender, disease duration, and prior relapse history.
• Statistical evaluation of annual attack rates before and after IFNα2a therapy.

Main Results:

• IFNα2a therapy demonstrated high response rates (93.7%) and significantly reduced the annual attack rate (from 4.03 to 0.58 attacks/year, P < 0.001).
• Multivariable analysis identified older age as a significant factor associated with a lower relapse rate.
• Improvement in visual acuity was statistically significant (P = 0.018).

Conclusions:

• IFNα2a therapy is effective in controlling relapses and improving visual acuity in Behçet uveitis.
• Older age may be a favorable prognostic indicator for sustained remission in BU patients undergoing IFNα2a treatment.
• Female gender, initially suggested as a positive prognostic factor, was not significant in multivariable analysis.